Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S) meets the primary endpoints in the phase-2 clinical trial of the drug candidate RNX-051.
November 16 2023 - 6:17AM
Pharma Equity Group’s subsidiary (Reponex Pharmaceuticals A/S)
meets the primary endpoints in the phase-2 clinical trial of the
drug candidate RNX-051.
16 November 2023
Company Announcement no. 45
Pharma Equity Group’s subsidiary
(Reponex Pharmaceuticals A/S) meets the primary endpoints in the
phase-2 clinical trial of the drug candidate RNX-051.
Reponex Pharmaceuticals A/S (Reponex) today
announced positive preliminary results from the phase-2 clinical
trial of the drug candidate RNX-051.
Reponex’s MEFO-trial concerns the treatment of
patients with right-sided colon cancer and right-sided colon
polyps/adenomas (precursors of cancer) with the Company’s drug
candidate RNX-051.
The trial’s primary endpoints, relating to a
quantitative change in biofilm, were met with the group of patients
having adenomas. ‘Topline’ results show that treatment with RNX-051
removes biofilm from the healthy intestinal mucosa. In patients
with colon cancer, it further removes the biofilm from the zone
adjacent to the cancer tumor in those patients who have a
particularly large amount of biofilm before treatment.
In patients with RNX-051-treated cancer
precursors, compared to non-treated cancer precursors, a higher
presence of special immune cells was found that are of crucial
importance for the immune system's ability to prevent the
development of cancer from its precursors. Likewise, in patients
with colon cancer, a more favorable combination of immune cells was
found in the tumor after treatment with RNX-051. Within 2 weeks of
treatment with RNX-051, it was possible to show that a single
treatment led to an increase in the cell types known to be crucial
for the immune system’s killing of cancer cells.
With these results, the study has shown a
mechanism that gives reason to assume that the treatment can be
incorporated into future treatments that can prevent the
development of cancer from the early stages, and in combination
with other treatment such as immunotherapy or similar forms of
cancer treatment.
Complete analysis of the study’s results is
expected to be ready early in 2024.
Contact person – Investor
Relations
On the Company’s website
www.pharmaequitygroup.com further information and all published
announcements can be found.
Inquiries regarding relations with investors and
the stock market can be directed to:
Thomas Kaas Selsø, CEO, Phone: +45 4022 2114
E-mail: investor@pharmaequitygroup.com
About Pharma Equity Group
A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring the
utmost success and impact of Reponex Pharmaceuticals' medical
projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
- 2023 11 16 - Announcement no. 45 - UK
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jul 2023 to Jul 2024